Osimertinib mesylate is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC)… Read more
Osimertinib mesylate is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor indicated for the treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in patients with specific EGFR mutations, such as exon 19 deletions, exon 21 L858R substitutions, or the T790M resistance mutation. This category provides essential analytical reference standards for osimertinib mesylate, including the active pharmaceutical ingredient, its pharmacopeial and non-pharmacopeial impurities, metabolites, and stable isotope-labelled compounds. Laboratories rely on these high-quality materials to support rigorous analytical testing, quality control, and method validation workflows. Specifically, these standards are vital for impurity profiling, allowing researchers to accurately identify and quantify related substances in drug formulations. By providing characterized materials for use in stability studies and assay development, these compounds ensure reliable analytical performance and help maintain consistent standards in pharmaceutical research and manufacturing.